In this review, we summarize novel clinical data on multiple myeloma (MM) that 
were presented at the 2019 annual meeting of the American Society of Hematology. 
The Master trial showed that a response-adapted approach may effectively guide 
therapeutic decisions in terms of treatment intensification after autologous 
transplantation among patients with newly diagnosed MM. The Alcyone study 
confirmed the superiority of adding daratumumab to the backbone combination of 
bortezomib, melphalan, and dexamethasone among diagnosed MM patients unfit for 
transplantation, which resulted in a significant overall survival benefit. The 
Candor trial showed that the addition of daratumumab to carfilzomib and 
dexamethasone is associated with a significant benefit in progression-free 
survival among patients with relapsed/refractory MM after 1 to 3 prior lines of 
therapy. Novel agents including selinexor- and venetoclax-based combinations 
offer new therapeutic choices for relapsed/refractory MM. Furthermore, the 
trispecific CC-93269 represents the new generation of highly active T-cell 
engagers. Chimeric antigen receptor T-cell constructs show significant efficacy 
among patients with heavily pretreated relapsed/refractory MM; however, the 
sustainability of responses remains a challenge.